Risk prediction of hepatitis B or C or HIV among newly diagnosed cancer patients
- 22 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 115 (6), 703-711
- https://doi.org/10.1093/jnci/djad053
Abstract
Screening for viral infection in cancer patients is inconsistent. A mechanism to readily identify cancer patients at increased risk of existing or prior viral infection could enhance screening efforts while reducing costs. We identified factors associated with increased risk of past or chronic hepatitis virus B, hepatitis virus C, or HIV infection before initiation of systemic cancer therapy. Data were from a multicenter prospective cohort study of 3051 patients with newly diagnosed cancer (SWOG-S1204) enrolled between 2013 and 2017. Patients completed a survey with questions pertaining to personal history and behavioral, socioeconomic, and demographic risk factors for viral hepatitis or HIV. We derived a risk model to predict the presence of viral infection in a random set of 60% of participants using best subset selection. The derived model was validated in the remaining 40% of participants. Logistic regression was used. A model with 7 risk factors was identified, and a risk score with 4 levels was constructed. In the validation cohort, each increase in risk level was associated with a nearly threefold increased risk of viral positivity (odds ratio = 2.85, 95% confidence interval = 2.26 to 3.60, P < .001). Consistent findings were observed for individual viruses. Participants in the highest risk group (with >3 risk factors), comprised of 13.4% of participants, were 18 times more likely to be viral positive compared with participants with no risk factors (odds ratio = 18.18, 95% confidence interval = 8.00 to 41.3, P < .001). A risk-stratified screening approach using a limited set of questions could serve as an effective strategy to streamline screening for individuals at increased risk of viral infection.Funding Information
- National Institutes of Health
- National Cancer Institute (UG1CA189974)
This publication has 22 references indexed in Scilit:
- Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor ChemotherapyAnnals of Internal Medicine, 2015
- Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United StatesJournal of Clinical Oncology, 2015
- Socioeconomic status in HCV infected patients – risk and prognosisClinical Epidemiology, 2013
- The evolving epidemiology of HIV/AIDSAIDS, 2012
- Evolving epidemiology of hepatitis C virusClinical Microbiology & Infection, 2011
- Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factorsJournal of Medical Virology, 2010
- Cancer and disparities in health: Perspectives on health statistics and research questionsCancer, 2008
- Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during ChemotherapyAnnals of Internal Medicine, 2008
- Epidemiology of hepatitis B virus infection in the Asia–Pacific regionJournal of Gastroenterology and Hepatology, 2000
- Regressions by Leaps and BoundsTechnometrics, 1974